Instil Bio, Inc. (TIL): Price and Financial Metrics


Instil Bio, Inc. (TIL): $6.00

-1.93 (-24.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TIL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TIL Stock Price Chart Interactive Chart >

Price chart for TIL

TIL Price/Volume Stats

Current price $6.00 52-week high $23.68
Prev. close $7.93 52-week low $4.34
Day low $4.34 Volume 5,801,200
Day high $7.88 Avg. volume 430,996
50-day MA $8.70 Dividend yield N/A
200-day MA $14.68 Market Cap 775.76M

Instil Bio, Inc. (TIL) Company Bio


Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.


TIL Latest News Stream


Event/Time News Detail
Loading, please wait...

TIL Latest Social Stream


Loading social stream, please wait...

View Full TIL Social Stream

Latest TIL News From Around the Web

Below are the latest news stories about Instil Bio Inc that investors may wish to consider to help them evaluate TIL as an investment opportunity.

Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Patients enrolled and recruitment ongoing in Phase 2 trial of ITIL-168 in melanoma (DELTA-1)Fast Track Designation granted by FDA for ITIL-168 in metastatic melanomaCoStAR mechanism of action data presented at SITC 2021Successful pre-IND meeting for ITIL-306 DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or (TIL), therapies for the treatment of patients with cance

Yahoo | November 15, 2021

Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced poster presentations demonstrating pre-clinical data of the CoStimulatory Antigen Receptor (CoStAR) platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2021), held from November 10-14, 2021. Instil also presen

Yahoo | November 15, 2021

Was The Smart Money Right About Instil Bio, Inc. (TIL)?

In this article we are going to use hedge fund sentiment as a tool and determine whether Instil Bio, Inc. (NASDAQ:TIL) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, […]

Yahoo | November 10, 2021

Instil Bio to Present at Upcoming Investor Conferences in November

DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in two upcoming investor conferences in November: Cowen 5th Annual IO Next SummitMonday, November 15, 2021Session Time: 4:45 PM – 5:05 PM ETLive Session Link: https://wsw.com/admin/link/presenter.aspx?

Yahoo | November 8, 2021

Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress

DALLAS, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, announced today that a subset analysis of treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients with checkpoint inhibitor-refractory advanced cutaneous melanoma was presented today at the 2021 European Society for M

Yahoo | September 16, 2021

Read More 'TIL' Stories Here

TIL Price Returns

1-mo -21.57%
3-mo -44.44%
6-mo -72.48%
1-year -66.29%
3-year N/A
5-year N/A
YTD -64.93%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6277 seconds.